Medoclav (Amoxicillin, Clavulanic Acid)

Amoxicillin interferes with bacterial cell‑wall synthesis by binding to penicillin‑binding proteins, causing cell lysis. Clavulanic acid inhibits β‑lactamase enzymes that many resistant bacteria produce, protecting amoxicillin from degradation and extending its activity against β‑lactamase‑producing organisms.

The dose of Medoclav is individualized by the prescribing clinician. Factors such as the type and severity of infection, patient age, weight, renal and hepatic function, and concomitant medications influence the selected dosage and duration of therapy.

Medoclav is classified as pregnancy category B1, indicating that animal studies have not shown risk to the fetus and there are no adequate human studies. It may be used during pregnancy only when the expected benefit justifies any potential risk. Small amounts are excreted in breast milk; breastfeeding decisions should be made with a health‑care provider.

To order Medoclav, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain handling where required) and assistance with import documentation.

Plain amoxicillin is vulnerable to degradation by bacterial β‑lactamases, limiting its spectrum against resistant strains. Medoclav adds clavulanic acid, a β‑lactamase inhibitor, which protects amoxicillin from enzymatic breakdown, thereby expanding coverage to include many β‑lactamase‑producing organisms and improving clinical efficacy in mixed infections.

Medoclav must be stored at 2‑8 °C (refrigerated). Keep the vials in their original packaging, protect them from light, and do not freeze or shake the solution. If the product reaches room temperature for a short period, it may be used, but it should be returned to refrigeration promptly.

Medoclav is given as an intravenous infusion. The solution is typically diluted in an appropriate compatible fluid and administered over a period specified by the prescriber, often 30 minutes to 1 hour, depending on the clinical situation and patient tolerance.

Serious risks include severe allergic reactions such as anaphylaxis, rare but life‑threatening skin conditions like Stevens‑Johnson syndrome, Clostridioides difficile‑associated colitis leading to severe diarrhea, and significant liver enzyme elevations indicating hepatic injury. Patients should be monitored closely for any signs of these events.

Medoclav should be avoided in individuals with a known hypersensitivity to amoxicillin, clavulanic acid, or any other β‑lactam antibiotics. It is also contraindicated in patients with a history of severe hepatic impairment or those who have previously experienced severe reactions to β‑lactamase inhibitors.